In the context of HPV-negative SCCHN, we and others have shown previously that metabolic phenotype and associated therapeutic opportunities are dictated by TP53 status, with mutational loss of wild-type p53 function conferring a metabolic switch away from oxidative phosphorylation and towards glycolytic dependence [13,14,15]. Here, TP53 is linked to head and neck squamous cell carcinoma.